Long-term Safety and Efficacy of the Derivo Embolization Device in aSingle-center Series.

Abstract

This study analyzes the long-term clinical and angiographic outcomes of the Derivo Embolization Device (DED), an advanced flow diverter device with an electropolished surface, for the treatment of intracranial aneurysms. Aconsecutive series of 101 patients (mean age: 58years, 72% female) treated with the DED for 122 aneurysms at asingle center between 2017 and 2023 was retrospectively analyzed for major (change in National Institutes of Health Stroke Scale [NIHSS] score ≥ 4points) and minor (change in NIHSS score < 4points) neurological events, procedural morbidity (increase of at least one point on the modified Rankin Scale), and angiographic results. There were 14(11%) recurrent aneurysms, 15(12%) ruptured aneurysms, 26(21%) posterior circulation aneurysms and 16(13%) fusiform or dissecting aneurysms. Device deployment failed in 1case (1%). Procedure-related symptomatic procedural complications consisted of 2(2%) major events (1major stroke and 1vessel perforation with intracranial hemorrhage and infarction) and 6minor events (6minor strokes). Procedural morbidity was 5%. There were no late ischemic or hemorrhagic events during follow-up. Complete and favorable aneurysm occlusion was achieved in 54% (40/74) and 62% (46/74) at amean of 5months, 71% (27/38) and 87% (33/38) at amean of 12months, and 76% (25/33) and 97% (32/33) at amean of 35months, respectively. The results demonstrate progressive aneurysm occlusion beyond 12months after DED implantation with an almost 100% favorable occlusion rate. Procedural morbidity was low and there were no late complications.